Stock AMNI AMNIOTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amniotics AB

Equities

AMNI

SE0015961016

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
0.0055 SEK -8.33% Intraday chart for Amniotics AB +10.00% -38.89%
05-20 Magle Chemoswed Holding AB (OM:MAGLE) cancelled the acquisition of 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other. CI
03-22 Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 174.5 19.04 24.39 15.03 - -
Enterprise Value (EV) 1 130.5 19.04 24.39 7.132 15.03 15.03
P/E ratio -3.25 x - - - - -
Yield - - - - - -
Capitalization / Revenue - - - - - 0.14 x
EV / Revenue - - - - - 0.14 x
EV / EBITDA -2.53 x -0.42 x -0.91 x -0.3 x -0.64 x 0.18 x
EV / FCF -8,346,944 x - - - - -
FCF Yield -0% - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 16,066 16,066 2,710,548 2,733,052 - -
Reference price 2 10.86 1.185 0.009000 0.005500 0.005500 0.005500
Announcement Date 2/17/22 1/19/23 2/22/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.0376 - - - - - 107.9
EBITDA 1 - -51.62 -44.9 -26.77 -23.7 -23.6 81.9
EBIT 1 - -53.62 -46.69 -29.07 -23.7 -23.6 81.9
Operating Margin - - - - - - 75.9%
Earnings before Tax (EBT) 1 - -53.62 -48.05 -30.87 -23.7 -23.6 81.9
Net income 1 -31 -53.62 -48.05 -30.87 -23.7 -23.6 81.9
Net margin -82,329.93% - - - - - 75.9%
EPS - -3.340 - - - - -
Free Cash Flow - -15.63 - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/18/21 2/17/22 1/19/23 2/22/24 - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 44 - - 7.9 - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - -15.6 - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 3/18/21 2/17/22 1/19/23 2/22/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AMNIOTICS AB Stock Amniotics AB
-38.89% 1.42M
MODERNA, INC. Stock Moderna, Inc.
+19.41% 45.51B
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.36B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AMNI Stock
  4. Financials Amniotics AB